Prof. Martine Rémy-Jardin, PhD.

Not only does the technology slash radiation dose but it also cuts exam time by 75%, reported a team led by Dr. Martine Remy-Jardin, PhD, of the University Centre of Lille, France -- findings that are good news for patients, especially those who may have to undergo multiple exams.

"PCCT acquisitions provided similar morphologic image quality and superior perfusion imaging at lower radiation dose," she noted.

The results came from two studies the team conducted. The first included 71 patients who had PCCT CCTA exams; these data were compared with data from a matched cohort of patients who had dual-source CCTA imaging. The dual-source cohort was considered to be group 1 and the PCCT cohort was group 2.

Group 2 exams showed a significantly lower dose length product (DLP) compared with group 1 exams -- at 172.6 mGy*cm versus 339.4 mGy*cm (p < 0.001) -- and they also had a much shorter acquisition time (0.93 seconds vs. 3.98 seconds, p < 0.0001). There were no significant differences in attenuation values in the central pulmonary arteries or the aorta on images taken at 70 keV, the team reported. The researchers did find that Hounsfield unit (HU) values were higher on the PCCT images compared with the dual-source CT images, at 9.55 HU and 6.88 HU, respectively.

In a related presentation given during the same session, Rémy-Jardin shared findings from a second study that further confirmed how PCCT for CCTA reduces radiation doses compared with conventional CT. For this research, the investigators evaluated three protocols:

• A standard CCTA protocol at the arterial phase (group 1, referred for suspicion of pulmonary embolism over a 9-month period and scanned with either dual-source CT [284 patients] or PCCT [345 patients])
• A venous-phase CCTA protocol (group 2, scanned with dual-source CT for thoracic cancer follow-up, 76 patients)
• A noncontrast CT protocol (group 3, scanned with PCCT for interstitial lung disease, 112 patients)

The team found that PCCT reduced dose length product (DLP) across all patient groups, but particularly in group 1.

"This study demonstrates substantial dose reduction with PCCT compared to [conventional] CT," Rémy-Jardin and colleagues concluded.

Editor's Note: For a PCCT video interview with Rémy-Jardin conducted at the French national congress of radiology, JFR, in October 2022, go to our report from the Paris congress.